Immunotherapy for Infectious Diseases

Tuberculosis and Other Mycobacterial Infections 299
95. Goletti D, Weissman D, Jackson RW, et al. Effect of M. tuberculosis on HIV replication.
Role of immune activation. J Immunol 1996; 157:1271–1278.
96. Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated course
of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med
1995; 151:129–135.
97. Wallis RS, Helfand MS, Whalen C, et al. Immune activation, allergic drug toxicity, and
mortality in HIV-positive tuberculosis. Tuber Lung Dis 1996; 77:516–523.
98. Cooper AM, Roberts AD, Rhoades ER, Callahan JE, Getzy DM, Orme IM. The role of
interleukin-12 in acquired immunity to M. tuberculosis infection. Immunology 1995;
84:423–432.
99. Flynn JL, Goldstein MM, Triebold KJ, Sypek J, Wolf S, Bloom BR. IL-12 increases resistance
of BALB/c mice to M. tuberculosis infection. J Immunol 1995; 155:2515–2524.
100. Johnson BJ, Ress SR, Willcox P, et al. Clinical and immune responses of tuberculosis
patients treated with low-dose IL-2 and multidrug therapy. Cytokines Mol Ther 1995;
1:185–196.
101. Johnson BJ, Bekker LG, Rickman R, et al. rhuIL-2 adjunctive therapy in multidrug resistant
tuberculosis: a comparison of two treatment regimens and placebo. Tuber Lung Dis
1997; 78:195–203.
102. Hirsch CS, Ellner JJ, Blinkhorn R, Toossi Z. In vitro restoration of T cell responses in
tuberculosis and augmentation of monocyte effector function against M. tuberculosis by
natural inhibitors of transforming growth factor beta. Proc Natl Acad Sci USA 1997;
94:3926–3931.
103. Bermudez LE, Young LS. Tumor necrosis factor, alone or in combination with IL-2, but
not IFN-gamma, is associated with macrophage killing of M. avium complex. J Immunol
1988; 140:3006–3013.
104. Bermudez LE, Stevens P, Kolonoski P, Wu M, Young LS. Treatment of experimental disseminated
M. avium complex infection in mice with recombinant IL-2 and tumor necrosis
factor. J Immunol 1989; 143:2996–3000.
105. Jeevan A, Asherson GL. Recombinant interleukin-2 limits the replication of Mycobacterium
lepraemurium and Mycobacterium bovis BCG in mice. Infect Immun 1988;
56:660–664.
106. Akuffo H, Kaplan G, Kiessling R, et al. Administration of recombinant interleukin-2
reduces the local parasite load of patients with disseminated cutaneous leishmaniasis.
J Infect Dis 1990; 161:775–780.
107. Hancock GE, Cohn ZA, Kaplan G. (1989) The generation of antigen-specific, major histocompatibility
complex-restricted cytotoxic T lymphocytes of the CD4� phenotype.
Enhancement by the cutaneous administration of interleukin 2. J Exp Med 169:909–919.
108. Kaplan G, Kiessling R, Teklemariam S., et al. The reconstitution of cell-mediated immunity
in the cutaneous lesions of lepromatous leprosy by recombinant interleukin 2. J Exp
Med 1989; 169:893–907.
109. Kaplan G, Britton WJ, Hancock GE, et al. The systemic influence of recombinant interleukin
2 on the manifestations of lepromatous leprosy. J Exp Med 1991; 173:993–1006.
110. Nathan CF, Kaplan G, Levis WR, et al. Local and systemic effects of intradermal recombinant
interferon-gamma in patients with lepromatous leprosy. N Engl J Med 1986;
315:6–15.
111. Holland SM, Eisenstein EM, Kuhns DB, et al. Treatment of refractory disseminated nontuberculous
mycobacterial infection with interferon gamma. A preliminary report. N Engl
J Med 1994; 330:1348–1355.
112. Squires KE, Brown ST, Armstrong D, Murphy WF, Murray HW. Interferon-gamma treatment
for M. avium-intracellular complex bacillemia in patients with AIDS [letter]. J Infect
Dis 1992; 166:686–687.